KRAS and metastatic neoplasm: In the context of metastatic disease, De Giglio et al. investigated the prevalence of Kirsten rat sarcoma viral oncogene (KRAS) exon 2 p.G12C mutations in a consecutive cohort of 24 patients with non-small cell lung cancer (NSCLC).